5th Edition of Euro-Global Conference on Biotechnology and Bioengineering
September 18-20 | Hybrid Event
CRISPR & Genome Editing Technologies
The advent of CRISPR & genome editing technologies has ushered in a new era of genetic precision, enabling targeted modifications with unprecedented accuracy. CRISPR-Cas systems allow scientists to cut, delete, or replace DNA sequences in a wide range of organisms, offering therapeutic possibilities for genetic diseases, cancer, and infectious conditions. Beyond CRISPR, novel editing tools like base editors and prime editors are expanding the genome editing toolkit. Researchers are now combining CRISPR & Genome Editing Technologies with delivery platforms such as viral vectors and nanoparticles to improve efficiency and specificity. These tools are also critical for functional genomics, crop enhancement, and synthetic biology. As ethical and regulatory frameworks evolve, genome editing remains one of the most transformative technologies in modern biotechnology.
Michele Mishto
Francis Crick Institute, United Kingdom
Thomas J Webster
Brown University, United States
Murray Moo Young
University of Waterloo, Canada
Assad Al Ammar
Specialty Enzymes and Probiotics, United States
Tina Moller Tagmose
Novo Nordisk A/S, Denmark
Yin Ying Ho
Agency for Science, Technology and Research (A*STAR), Singapore
Timea Gerzsenyi
University of Miskolc, HungarySubmit your abstract Today
Title : Targeting noncanonical epitopes in anti-cancer immunotherapy
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Effect of maltogenic amylase, high-performance maltogenic amylase enzymes, and Bacillus coagulans probiotic bacteria on the shelf life and other properties of baked bread and tortilla
Assad Al Ammar, Specialty Enzymes and Probiotics, United States
Title : Solving the challenges of engineering an ultra-long acting insulin
Tina Moller Tagmose, Novo Nordisk A/S, Denmark
Title : The lines of antigen-antibody interactions in vitro and their significance for sensitive and specific antigen and antibody assays, including hybrid ELISAs, and for the possibility of more efficacious vaccines
Viggo Bitsch, Retired, Independent Researcher, Denmark
Title : Lignocellulosic biomass to biofuels and biochemicals: Microbial innovations for a sustainable future
Gunjan Mukherjee, Chandigarh University, India
Title : Eliminating implant infection: 30,000 nanotextured implants in humans with no failure
Thomas J Webster, Brown University, United States